FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:2005-2006 June 24, 1999 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Celecoxib (Celebrex), a cyclooxygenase (COX)-2–specific nonsteroidal antiinflammatory drug (NSAID), was recently introduced in the U.S. market. COX-2 is induced in inflammation, whereas COX-1 produces protective prostaglandins in the stomach. Because of its specificity for COX-2, celecoxib is less likely to cause gastric injury. A one-week endoscopic study of gastrointestinal mucosal effects in phase 2 trials showed that gastric ulcers developed in 19 percent of the subjects receiving naproxen, whereas no ulcers developed in the subjects receiving celecoxib or placebo.¹ We describe a patient in whom NSAID-induced gastropathy developed while she was taking celecoxib.

A 69-year-old woman presented . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kulik, A., Ruel, M., Bourke, M. E., Sawyer, L., Penning, J., Nathan, H. J., Mesana, T. G., Bedard, P. (2004). Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial. Eur. J. Cardiothorac. Surg. 26: 694-700 [Abstract] [Full Text]  
• HALTER, F, TARNAWSKI, A S, SCHMASSMANN, A, PESKAR, B M (2001). Cyclooxygenase 2{---}implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 49: 443-453 [Abstract] [Full Text]